Find out all you need to know about Herceptin (trastuzumab) for early and more advanced HER2-positive breast cancer, including what to expect, outcomes, side effects, and more.

In the NeoSphere study, various combinations of a new HER2-targeted agent called pertuzumab, Herceptin and chemothery were studied in early-stage breast cancer patients with encouraging results. When ...

Herceptin is approved for the treatment of early-stage breast cancer that is Human Epidermal Growth Factor Receptor 2-positive (HER2+) and has spread into the lymph nodes, or is HER2+ and has not ...

The FDA will allow Herceptin, a biological cancer drug, to be used to treat an aggressive type of breast cancer after surgery. According to the FDA decision, announced yesterday, Herceptin may now ...

If you have early-stage HER2-positive breast cancer, here’s good news: There are more treatment options than ever. They can help you live longer while you enjoy a good quality of life.

In 1998, Herceptin (trastuzumab), the first medication to directly target HER2, was approved by the FDA. Oncologists usually start with this drug before trying other treatments.

Trastuzumab (or, Herceptin) works best when it's given with cancer-killing drugs, certain chemotherapies, and it has been a very significant advance. Now we measure HER2 by looking at the tissue ...

“Over the past 20 years, Herceptin has significantly advanced treatment of HER2-positive breast cancer,” said Sandra Horning, MD, chief medical officer and head of Global Product Development.

The breast cancer drug Herceptin prevents breast cancer from coming back in some women, new research shows. Moreover, Herceptin works just as well with and without Adriamycin, a chemotherapy drug ...

Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72.. Background: HER2 (human epidermal growth ...

Herceptin is sold in the US Genentech, in Japan by Chugai and internationally by Roche. Worldwide, nearly 600,000 patients with HER2-positive breast cancer have been treated with Herceptin since 1998.

An aggressive type of breast cancer — a HER2-positive tumor — often shrinks with Herceptin treatment, but side effects can be tough. Researchers say a shorter course of the drug may be a good ...